- Home
- TIL vs YMAB Comparison
TIL vs YMAB Comparison
Compare TIL & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- YMAB
- Stock Information
- Founded
- TIL 2018
- YMAB 2015
- Country
- TIL United States
- YMAB United States
- Employees
- TIL N/A
- YMAB N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TIL Health Care
- YMAB Health Care
- Exchange
- TIL Nasdaq
- YMAB Nasdaq
- Market Cap
- TIL 230.1M
- YMAB 192.4M
- IPO Year
- TIL 2021
- YMAB 2018
- Fundamental
- Price
- TIL $27.56
- YMAB $4.33
- Analyst Decision
- TIL Buy
- YMAB Buy
- Analyst Count
- TIL 5
- YMAB 11
- Target Price
- TIL $119.00
- YMAB $17.55
- AVG Volume (30 Days)
- TIL 503.4K
- YMAB 207.9K
- Earning Date
- TIL 08-12-2025
- YMAB 08-11-2025
- Dividend Yield
- TIL N/A
- YMAB N/A
- EPS Growth
- TIL N/A
- YMAB N/A
- EPS
- TIL N/A
- YMAB N/A
- Revenue
- TIL N/A
- YMAB $88,658,000.00
- Revenue This Year
- TIL N/A
- YMAB N/A
- Revenue Next Year
- TIL N/A
- YMAB $15.15
- P/E Ratio
- TIL N/A
- YMAB N/A
- Revenue Growth
- TIL N/A
- YMAB 4.92
- 52 Week Low
- TIL $9.62
- YMAB $3.55
- 52 Week High
- TIL $92.00
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- TIL 51.84
- YMAB 46.67
- Support Level
- TIL $27.01
- YMAB $4.46
- Resistance Level
- TIL $42.79
- YMAB $4.98
- Average True Range (ATR)
- TIL 5.01
- YMAB 0.33
- MACD
- TIL -1.00
- YMAB -0.05
- Stochastic Oscillator
- TIL 9.82
- YMAB 7.77
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.